论文部分内容阅读
●刚刚开始的联合用药疗法应该有助于阻止耐药性的发展,查尔斯·L·索耶斯指出。2001年,用于治疗慢性粒细胞白血病(CML)的药物伊马替尼获准上市,成为白血病治疗的转折点。从此以后,伊马替尼(由诺华公司上市,在美国商品名为Gleevec,在其他地区名为Glivec)和其他类似药物已经可以把被确诊患有CML的患者预期寿命从5-6年延长至10-20年。多重耐药性这种疗法的成功在于在病程早期就使用伊马替尼,随后,对于出现耐药反应的患者,应用4种新一代药物中的一种。“实验证明,这样的循序治疗方法增加了多重耐药性的风险。”目前的治疗方案是循序渐进的:当病人服用某种药物不再有效的时候,就转而使用另一种。但实验
● The newly started combination therapy should help stop the development of resistance, Charles L Sawyers points out. In 2001, imatinib, the drug used to treat chronic myeloid leukemia (CML), was approved for market launch as a turning point in the treatment of leukemia. Since then, imatinib (marketed by Novartis, Gleevec in the United States and Glivec elsewhere) and other similar drugs has been able to extend the life expectancy of patients diagnosed with CML from 5-6 years 10-20 years. Multidrug Resistance The success of this therapies lies in the use of imatinib at an early stage of the disease, followed by one of the four next-generation drugs in patients who develop resistance. “Experiments have shown that such sequential therapy increases the risk of multiple drug resistance.” "Current treatment options are gradual: when the patient is no longer effective with a given drug, he or she is switching to another. But experiment